Navigation Links
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Date:7/18/2014

ode, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

Disclosures are therefore required in the shares of AbbVie and Shire plc.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror

and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Takeover Panel's Market Surveillance Unit on +4
'/>"/>

SOURCE AbbVie Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Star Scientific and Rock Creek Pharmaceuticals Announce the Publication of a Peer-Reviewed Article about the ASAP Clinical Trial Showing Immune System Support in Hashimotos Thyroiditis
2. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the October 2013 Digital Edition Now Available Online and in the App Store
3. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
4. Labome: The Gateway to the Perfect Antibody -- Labome Antibody Review Database Has Now Reached 10,000 Peer-Reviewed Formal Publications
5. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
6. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
7. India Pharmaceutical Sector Reviewed by Kelly Scientific Publications in In-demand Report Now Available at MarketPublishers.com
8. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
9. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
10. MarketResearch.com Announces Distribution of Kelly Scientific Publications
11. Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 /PRNewswire/ ... a leader in synthetic biology, today announced it has ... (OSF), the pioneering agricultural company behind the ... apple. Through the acquisition, Intrexon expands its food programs ... and convenient for consumers while providing economic benefit throughout ...
(Date:2/27/2015)... , Feb. 27, 2015 A paper ... NCATS rare-diseases portfolio " in Science Translational ... financing technique to reduce the risk associated with ... potentially unlock new levels of funding for developing ... of a unique collaboration between scientists at the ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... TORONTO, May 6 /PRNewswire/ - Dalton ... services provider, and Thermo Fisher Scientific,have ... Dalton will use a proprietary,Thermo Fisher ... for,pharmaceutical use., Utilizing enzyme-based technology ...
... Years of Advertising Awards with ,Blue Ladies, a, ... Replacements for Women, CHICAGO, May 6 ... healthcare advertising,campaigns, scored top honors in the medical ... April 17. The awards ceremony was part of,the ...
... 6 Novavax, Inc. (Nasdaq:,NVAX) today announced that it ... press release to be issued after 8:00 a.m. Eastern ... investor conference call to discuss its,financial results at 10:00 ... will,be hosted by Novavax President and Chief Executive Officer ...
Cached Biology Technology:Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development 2Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development 3AbelsonTaylor Captures DTC Gold 2AbelsonTaylor Captures DTC Gold 3Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call 2
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... - Old muscle got a shot of youthful vigor in ... California, Berkeley, setting the path for research on new treatments ... and Parkinson,s diseases. In a new study to be ... journal Nature , researchers identified two key regulatory pathways ...
... they are living and working at 60 feet below the ... survive transplanting after a disturbance, such as a storm, while ... the combined effects of hurricanes, global warming, and increased boat ... become a priority among those who are concerned. Using ...
... University of Delaware has received $400,000 from the National ... an ocean observing system for the Mid-Atlantic region, spanning ... Mass., and out to the continental shelf. Nearly 25 ... coast. The initiative is part of the national ...
Cached Biology News:Stem cell researchers give old muscle new pep 2Stem cell researchers give old muscle new pep 3Stem cell researchers give old muscle new pep 48-day undersea mission begins experiment to improve coral reef restoration 2UD nets NOAA funding for Mid-Atlantic ocean observing 2
... ProFound Label Transfer Sulfo SBED Protein:Protein Interaction ... as Label Transfer has rapidly gained traction ... interaction discovery. A growing number of publications ... Label Transfer Reagent to study a variety ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
Biology Products: